Sygnature Discovery, thas appointed Dr Bill Marathias as Vice President of Business Development for the US to assist with the company’s international growth plans.
https://european-biotechnology.com/wp-content/uploads/2024/04/Eb_online_appointments_sygnature.JPG700700h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-06-01 15:59:562018-06-01 15:59:56Sygnature Discovery appoints Dr Bill Marathias
Bavarian Nordic A/S today announced the appointment of Henrik Juuel to the position of Executive Vice President and Chief Financial Officer. Mr. Juuel is currently the CFO of Orexo AB.
https://european-biotechnology.com/wp-content/uploads/2024/04/eb_online_appointment_juuel.jpg420420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-05-31 16:29:422018-05-31 16:29:42Bavarian Nordic to appoint Henrik Juuel as CFO
Brain disease specialist Denali Therapeutics will buy all outstanding shares in British F-Star Gamma Ltd from F-Star instead licencing bispecific antibody candidates that can cross the blood-brain barrier (BBB) co-developed under an agreement dating back to 2016.
Nordic Nanovector ASA today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the company’s Annual General Meeting on 30 May 2018.
Roche announced that atezolimumab plus chemotherapy met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) as first-line treatment of stage IV nonsquamous non small cell lung cancer (NSCLC).
Nouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).
https://european-biotechnology.com/wp-content/uploads/2024/04/nouscom_woolfson.jpg270270h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2018-05-29 13:40:152018-05-29 13:40:15Nouscom Appoints Adrian Woolfson as CMO
Following reports of an increase in mortality in a study that combined Genmab’s anti-CD38 daratumumab with a PD-L1 blocker, Genmab’s partner Janssen has stopped a study combining daratumumab with its PD1 blocker JNJ-63723283 in multiple myeloma.
Targovax ASA’s cancer immunotherapy TG01 significantly prolonged 2-year overall survival of patients with resected pancreatic cancer versus standard therapy. Targovax’ shares were up 16% on Thursday evening.
https://european-biotechnology.com/wp-content/uploads/2024/04/Bildschirmfoto_2018-05-25_um_05.06.54.png548665Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2018-05-24 13:52:532018-05-24 13:52:53Targovax drug boosts 2-year OS in pancreatic cancer
Sygnature Discovery appoints Dr Bill Marathias
AppointmentsSygnature Discovery, thas appointed Dr Bill Marathias as Vice President of Business Development for the US to assist with the company’s international growth plans.
New epilepsy target discovered
Latest NewsFrench researchers have found a key driver of chronic epilepsy.
Bavarian Nordic to appoint Henrik Juuel as CFO
AppointmentsBavarian Nordic A/S today announced the appointment of Henrik Juuel to the position of Executive Vice President and Chief Financial Officer. Mr. Juuel is currently the CFO of Orexo AB.
Denali bags F-Star Gamma
Latest NewsBrain disease specialist Denali Therapeutics will buy all outstanding shares in British F-Star Gamma Ltd from F-Star instead licencing bispecific antibody candidates that can cross the blood-brain barrier (BBB) co-developed under an agreement dating back to 2016.
Rainer Boehm joins Nordic Nanovector Board of Directors
AppointmentsNordic Nanovector ASA today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the company’s Annual General Meeting on 30 May 2018.
Roche mets endpoints in first-line NSCLC study
Latest NewsRoche announced that atezolimumab plus chemotherapy met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) as first-line treatment of stage IV nonsquamous non small cell lung cancer (NSCLC).
Nouscom Appoints Adrian Woolfson as CMO
AppointmentsNouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).
New way to safer CAR-T cell therapies
Latest NewsInterleukin 1 (IL-1) blockers may prevent serious adverse events triggered by CAR-T cell therapies, according to two independent studies.
Janssen ends combo with daratumumab
Latest NewsFollowing reports of an increase in mortality in a study that combined Genmab’s anti-CD38 daratumumab with a PD-L1 blocker, Genmab’s partner Janssen has stopped a study combining daratumumab with its PD1 blocker JNJ-63723283 in multiple myeloma.
Targovax drug boosts 2-year OS in pancreatic cancer
Latest NewsTargovax ASA’s cancer immunotherapy TG01 significantly prolonged 2-year overall survival of patients with resected pancreatic cancer versus standard therapy. Targovax’ shares were up 16% on Thursday evening.